Leica Novocastra CD71 Mode D'emploi page 35

Antistoffer fra Leica Biosystems Newcastle Ltd skal brukes, som angitt, på enten frosne eller parafinlagrede snitt med spesifikke krav
til fiksering. Uventet antigenekspresjon kan forekomme, spesielt i neoplasma. Den kliniske tolkningen av fargede vevssnitt må omfatte
morfologiske analyser og evaluering av egnede kontroller.
Bibliografi – Generelt
1. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases
transmitted by blood and tissue; proposed guideline. Villanova, P.A. 1991; 7(9). Order code M29-P.
2. Battifora H. Diagnostic uses of antibodies to keratins: a review and immunohistochemical comparison of seven monoclonal and
three polyclonal antibodies. Progress in Surgical Pathology. 6:1–15. eds. Fenoglio-Preiser C, Wolff CM, Rilke F. Field & Wood, Inc.,
Philadelphia.
3. Nadji M, Morales AR. Immunoperoxidase, part I: the techniques and pitfalls. Laboratory Medicine. 1983; 14:767.
4. Omata M, Liew CT, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen: a
possible source of error in immunohistochemistry. American Journal of Clinical Pathology. 1980; 73:626.
5. Dong HY, Wilkes S and Yang H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation
stages: a comparative immunochemical study with glycophorin A and hemoglobin A. American Journal of Surgical Pathology. 2011;
35(5):723-732.
6. Magro G, Cataldo I, Amico P, et al. Aberrant expression of TfR1/CD71 in thyroid carcinomas identifies a novel potential diagnostic
marker and therapeutic target. Thyroid. 2011; 21(3):267-277.
7. Menier C, Rabreau M, Challier JC, et al. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive
hematopoiesis. Blood. 2004; 104(10):3153-3160.
Endringer i forhold til Forrige Utgave
Oppdatering av format for Forventede resultater, tillegg av oversatt tekst.
Utgivelsesdato
01 november 2018
CD71-309
Page 34